Top Brands for Cefpodoxime Proxetil: Your Go-To Guide

Cefpodoxime proxetil, a third-generation cephalosporin antibiotic, is widely utilized to treat a range of bacterial infections. With its effectiveness in battling respiratory tract infections, skin infections, and urinary tract infections, it is no wonder that various pharmaceutical companies have stepped up to manufacture this vital medication. Numerous brands offer cefpodoxime proxetil, each striving to combine efficacy with affordability to meet patient needs. Curious to discover which brands stand out in the market? Read on to uncover the top contenders.

Illustration of cefpodoxime proxetil

Best brands of cefpodoxime proxetil in 2025

Lupin

Lupin is a renowned pharmaceutical company that stands out as one of the best producers of cefpodoxime proxetil, a third-generation cephalosporin antibiotic. Known for its high purity and adherence to pharmacopoeial specifications, Lupin's cefpodoxime proxetil is widely prescribed, particularly in the 100 mg and 200 mg dosages, which dominate the market due to their efficacy and balanced safety profile. In 2024, the global cefpodoxime proxetil market, led by regions like North America and the Asia Pacific, was estimated at USD 15,245.2 million, with North America accounting for around 40% of the global revenue. Lupin's strong presence in these markets, coupled with its advanced manufacturing capabilities and stringent quality control, ensures the delivery of high-quality cefpodoxime proxetil. The company's commitment to innovation and compliance with regulatory standards further solidifies its position as a leading producer. For more information about their cefpodoxime proxetil, visit their dedicated page.

Ranbaxy Laboratories

Ranbaxy Laboratories is renowned for its high-quality production of cefpodoxime proxetil, a third-generation cephalosporin antibiotic. Their formulation ensures better bioavailability and dissolution, with micronized particles having a mean size of less than 30 microns and a surface area greater than 1.3 m²/g, enhancing the drug's efficacy. The company's process involves advanced techniques such as fluid energy milling and dry granulation to achieve optimal particle size distribution, with at least 90% of particles being less than 75 microns. This meticulous manufacturing process results in a pharmaceutical composition that releases over 88% of the drug within 10 minutes in a glycine buffer of pH 3.0. Ranbaxy's commitment to purity and yield is evident in their adherence to pharmacopoeial specifications. For detailed information, check their patent documentation.

Aurobindo Pharma

Aurobindo Pharma Limited is a renowned manufacturer of cefpodoxime proxetil, a third-generation cephalosporin antibiotic, known for its effectiveness against a wide spectrum of Gram-positive and Gram-negative bacteria. The drug, available in various formulations including flavored granules for oral suspension, ensures high bioavailability, with approximately 50% of the administered dose being absorbed systemically. Aurobindo Pharma's cefpodoxime proxetil products are marketed under several NDC codes, including 65862-140-01 and 65862-141-01, and are recognized for their quality and efficacy. In clinical trials, cefpodoxime proxetil has demonstrated a low discontinuation rate due to adverse events, with only 1.1% of patients discontinuing the medication. The drug's half-life ranges from 2.09 to 2.84 hours, ensuring sustained therapeutic levels. For detailed information, visit their official product page.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries, as one of the world's leading generic pharmaceutical companies, is renowned for its high-quality production of cefpodoxime proxetil, a crucial antibiotic. Founded in 1983, Sun Pharma has grown to become the fourth largest specialty generic pharmaceutical company globally, with revenues of $5.4 billion and a presence in over 100 countries. The company invests up to 6-8% of its global revenues in Research and Development, ensuring innovative and technologically complex products like cefpodoxime proxetil. With 43 manufacturing facilities, Sun Pharma produces a diverse portfolio of medicines, including generics, branded generics, and specialty products. Its U.S. business, which accounts for 30% of its global revenue, ranks Sun Pharma as a leading player in the generics market.

Cipla

Cipla, a renowned pharmaceutical company, is a significant producer of cefpodoxime proxetil, a broad-spectrum oral cephalosporin antibiotic. The company has forged strategic alliances, such as with UK-based Neolab, to enhance its market presence, particularly in the European market for off-patent drugs. Cipla's cefpodoxime proxetil products, including dry suspension formulations like Cefoprox50, contribute to the global market, which is expected to grow at a CAGR of 5.00% from 2024 to 2031, reaching USD 21,451.53 million by 2031. In 2024, the Asia Pacific region, where Cipla has a strong presence, held around 23% of the global revenue with a market size of USD 3,506.40 million. Cipla's products are known for their effectiveness and convenience, making them a preferred choice in managing bacterial infections.

Zydus Cadila

Zydus Cadila is a prominent producer of cefpodoxime proxetil, known for its high-quality formulations and widespread use in treating various bacterial infections. The company's product, MONOTAX O (cefpodoxime) and MONOTAX CV (cefpodoxime and clavulanic acid combination), is highly regarded for its efficacy and safety profile. With a global cefpodoxime proxetil market size estimated at USD 15,245.2 million in 2024, Zydus Cadila's contributions are significant, especially given the market's projected compound annual growth rate (CAGR) of 5% from 2024 to 2031. Zydus Cadila's formulations are preferred for their balanced approach between efficacy and safety, making them a standard prescription for adults. The company's commitment to pharmaceutical advancements and patient compliance has solidified its position in the market. For more information, visit the Zydus Cadila website.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a leading producer of cefpodoxime proxetil, known for its robust product pipeline and significant market presence. In FY23, the company achieved a revenue growth of 15% year-over-year, driven partly by its generics segment, which includes cefpodoxime proxetil. Dr. Reddy's launched 25 new products in FY23, contributing to its strong performance in the global generics market. The company's Pharmaceutical Services and Active Ingredients (PSAI) segment, which includes active pharmaceutical ingredients for cefpodoxime proxetil, saw a revenue of Rs. 29.1 billion in FY23, despite a 5% year-over-year decline due to price erosion and base business volume reductions. Dr. Reddy's continuous investment in R&D and new product launches solidifies its position as a top producer of cefpodoxime proxetil. For more information, visit their official website.

Mylan

Mylan is a prominent producer of cefpodoxime proxetil, known for its high-quality formulations and widespread market presence. The global cefpodoxime proxetil market, valued at USD 15,245.2 million in 2024, is expected to grow at a CAGR of 5.00% from 2024 to 2031, with Mylan contributing significantly to this expansion. North America, where Mylan has a strong presence, dominated the market in 2024 with around 40% of the global revenue. Mylan's formulations, including the 100 mg and 200 mg dosages, are preferred for their efficacy and balanced safety profile. The company's commitment to advancements in pharmaceutical formulations has enhanced the drug's effectiveness and patient compliance.

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a prominent manufacturer of cefpodoxime proxetil, known for its high-quality pharmaceutical products. The company's extensive experience and advanced manufacturing capabilities ensure the production of effective and reliable antibiotic treatments. In the global cefpodoxime proxetil market, which is projected to grow at a CAGR of 5% from 2024 to 2031, Glenmark Pharmaceuticals plays a significant role, particularly in regions like Asia Pacific where the market is expanding rapidly. The company's commitment to quality and innovation has made it a trusted name in the pharmaceutical industry. With a strong presence in various markets, Glenmark Pharmaceuticals continues to contribute significantly to the global healthcare sector.

Alkem Laboratories

Alkem Laboratories is a leading producer of cefpodoxime proxetil, standing as the fifth largest player in India's domestic formulation market with a 4.1% market share as of March 2023. The company dominates the anti-infective segment with a 10% market share and has multiple brands generating over Rs 100 crore in annual sales. Alkem's strong presence in the pharmaceutical industry, particularly in anti-infectives, positions it as a reliable producer of cefpodoxime proxetil. The global cefpodoxime proxetil market, in which Alkem participates, is projected to grow at a CAGR of 5% from 2024 to 2031, with the Asia Pacific region being a significant growth driver. Alkem's product quality and market leadership ensure it remains a key player in this expanding market. For more details, visit Alkem Laboratories.